tbuckley/cabot-search huggingface dataset:
Commentary
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
D &amp;amp; C `Essential' for Uterine Hemorrhage Control
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association between diaphragm use and urinary tract infection
Authors: S. D. Fihn
Journal: JAMA (1985)

We conducted independent case-control and retrospective cohort investigations to assess the relationship between diaphragm use and urinary tract infection (UTI). In the former, we compared diaphragm use and vaginal flora among 114 women with acute UTI and 85 women with acute urinary tract symptoms and no UTI. In the latter study, we ascertained the incidence of UTI in 192 diaphragm users and 182 women taking oral contraceptives during a mean follow-up of 9.4 months. Both studies demonstrated a significantly increased risk of UTI in diaphragm users: relative odds were 2.0 in the case-control study and the relative risk was 2.5 in the retrospective cohort study. Vaginal colonization with<i>Escherichia coli</i>was significantly greater in diaphragm users. The incidence of UTI in the cohort study was 26.6 per 1,000 patient-months for diaphragm users and 8.9 per 1,000 patient-months for women taking oral contraceptives. The increased risk of UTI in diaphragm users could not be attributed to differences in age, parity, sexual activity, or previous UTI. (<i>JAMA</i>1985;254:240-245)
DRUG NAMES
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Beat
Authors: Erin E. Dooley
Journal: Environmental Health Perspectives (2013)

Nickel-Tainted Flowers Taste Bad to BeesMetals can accumulate i n f l o w e r i n g p l a n t s grown in contaminated soils and have been found in honey samples collected near polluted sites.Investigators at the University of Pittsburgh now report that metal contamination of flowers may affect bumblebees' foraging behavior and potentially harm pollinator health. 1 In the study, bees spent 75% less time foraging on nickelcontaminated flowers compared with controls.Aluminum con tamination did not appear to deter the bees.However, exposure to either metal may interfere with bees' taste perception, agility, and working memory, all skills necessary for normal functioning.The results suggest that growing plants to bioremediate contaminated soil needs to be further examined with respect to its impact on pollinator populations.
Phenistix in Psychiatric Practice
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
241. A Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys
Authors: John R. Forsayeth, Jamie L. Eberling, Laura M. Sanftner, Zhu Zhen, Philip Pivirotto, John Bringas, Janet Cunningham, Krystof S. Bankiewicz
Journal: Molecular Therapy (2006)

The main medication for idiopathic Parkinson's disease (PD) is L-Dopa. Drug efficacy declines steadily in part because the converting enzyme, aromatic L-amino acid decarboxylase (AADC), is lost concomitantly with substantia nigra atrophy. Over the past decade, we have developed a gene therapy approach in which AADC activity is restored to the brain by infusion into the striatum of a recombinant adeno-associated virus carrying human AADC cDNA. We report here the results of an investigation of the relationship between vector dose and a series of efficacy markers, such as PET, L-Dopa response, and AADC enzymatic activity. At low doses of vector, no effect of vector was seen on PET or clinical response. At higher doses, a sharp improvement in both parameters was observed resulting in an approximate 50 percent improvement in L-Dopa response. The relationship between vector dose and AADC enzymatic activity in tissue extracts was linear. We conclude that little clinical improvement can be seen until AADC activity reaches a level that is no longer rate-limiting for conversion of clinical doses of L-Dopa into dopamine, or for trapping of the PET tracer, FMT. These findings have implications for the design and interpretation of clinical studies of AAV-hAADC gene therapy.Laura M. Sanftner is currently a scientist at Avigen. She stands to benefit from success in the clinical studies upon which this work is based. The main medication for idiopathic Parkinson's disease (PD) is L-Dopa. Drug efficacy declines steadily in part because the converting enzyme, aromatic L-amino acid decarboxylase (AADC), is lost concomitantly with substantia nigra atrophy. Over the past decade, we have developed a gene therapy approach in which AADC activity is restored to the brain by infusion into the striatum of a recombinant adeno-associated virus carrying human AADC cDNA. We report here the results of an investigation of the relationship between vector dose and a series of efficacy markers, such as PET, L-Dopa response, and AADC enzymatic activity. At low doses of vector, no effect of vector was seen on PET or clinical response. At higher doses, a sharp improvement in both parameters was observed resulting in an approximate 50 percent improvement in L-Dopa response. The relationship between vector dose and AADC enzymatic activity in tissue extracts was linear. We conclude that little clinical improvement can be seen until AADC activity reaches a level that is no longer rate-limiting for conversion of clinical doses of L-Dopa into dopamine, or for trapping of the PET tracer, FMT. These findings have implications for the design and interpretation of clinical studies of AAV-hAADC gene therapy. Laura M. Sanftner is currently a scientist at Avigen. She stands to benefit from success in the clinical studies upon which this work is based.
Biomagnetic Effects: A Consideration in Fusion Reactor Development
Authors: D. D. Mahlum
Journal: Environmental Health Perspectives (1977)

Fusion reactors will utilize powerful magnetic fields for the confinement and heating of plasma and for the diversion of impurities. Large dipole fields generated by the plasma current and the divertor and transformer coils will radiate outward for several hundred meters, resulting in magnetic fields up to 450 gauss in working areas. Since occupational personnel could be exposed to substantial magnetic fields in a fusion power plant, an attempt has been made to assess the possible biological and health consequences of such exposure, using the existing literature. The available data indicate that magnetic fields can interact with biological material to produce effects, although the reported effects are usually small in magnitude and often unconfirmed. The existing data base is judged to be totally inadequate for assessment of potential health and environmental consequences of magnetic fields and for the establishment of appropriate standards. Requisite studies to provide an adequate data base are outlined.
Use of optical immunoassay to diagnose streptococcal pharyngitis
Authors: J. C. Dale
Journal: JAMA (1997)

<h3>To the Editor.</h3> —In the article by Dr Gerber and colleagues<sup>1</sup>reporting an office-based multicenter investigation of the optical immunoassay (OIA) test for group A β-hemolytic streptococcal (GABHS) pharyngitis, the authors concluded that "with adequately trained personnel, negative OIA test results may not always need to be routinely confirmed with blood agar plate (BAP) cultures." We believe the authors' conclusions are based less on the quality of the testing personnel or the performance specifications of the OIA and more on the quality of the BAP culture procedure used in the study. Presumptive differentiation of GABHS and non—group A streptococci may be accomplished by the bacitracin test, in which a zone of inhibition is noted on a pure subculture of β-hemolytic colonies. Bacitracin disks placed on primary cultures on nonselective media, as was done in this study, may detect as little as 54% of group A streptococci.<sup>2</sup>We compared
Incorrect X-Axis, Y-Axis, and Panel Labels
Journal: JAMA Network Open (2019)

Kazuki Sudo, MD, PhD; Ken Kato, MD, PhD; Juntaro Matsuzaki, MD, PhD; Narikazu Boku, MD, PhD; Seiichiro Abe, MD, PhD; Yutaka Saito, MD, PhD; Hiroyuki Daiko, MD, PhD; Satoko Takizawa, PhD; Yoshiaki Aoki, BS; Hiromi Sakamoto, PhD; Shumpei Niida, PhD; Fumitaka Takeshita, PhD; Takahiro Fukuda, MD, PhD; Takahiro Ochiya, PhD
Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.
Authors: Nicolaus Kroeger, Avichai Shimoni, Maria Zagrivnaja, Francis Ayuk, Michael Lioznov, Heike Schieder, Boris Fehse, Tatjana Zabelina, Arnon Nagler, Axel Zander
Journal: Blood (2004)
Physiological Aspects of Free-Radical Reactions
Authors: Isao Yamazaki, Mamoru Tamura, Ryo Nakajima, Masao Nakamura
Journal: Environmental Health Perspectives (1985)

Enzymes which catalyze the formation of free radicals in vitro will catalyze similar reactions in vivo. We believe that the formation of some kinds of free radicals has definite physiological meanings in metabolism. In this sense, the enzymes forming such free radicals are concluded to be in evolutionally advanced states. Elaborated structure and function of enzymes such as horseradish peroxidase and microsomal flavoproteins support the idea. Deleterious and side reactions caused by free radicals are assumed to be minimized in vivo by localizing the reactions, but this assumption should be verified by future studies.
Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension
Authors: B. Raffestin, M. Leroy
Journal: European Respiratory Journal (2010)

Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertensionTo the Editors:We read with great interest the editorial by NAEIJE and vAN DE BORNE [1] on clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension.This editorial applies to the study of WENSEL et al.[2] investigating heart rate variability and baroreflex sensitivity in patients with severe pulmonary arterial hypertension (PAH).
Gomers
Authors: Valery A. Portnoi
Journal: JAMA (1980)

<h3>To the Editor.—</h3> The short but brilliant piece of art "Gomers" (243:2333, 1980) deserves the highest degree of praise. The case study of a 3-year-old patient successfully demonstrates that even if there are hopeless medical cases, they are not necessarily helpless. The little boy, Allan, using his childish naiveté, has asked the staff for help that is not considered in current practice as medical. Reading books to the sick child is, indeed, a more appropriate task for the parents. However, what if they are not around? Hopeless cases are presumably seen less frequently nowadays because of the establishment of scientific medicine. Yet, they are encountered in pediatrics, more often in adult practice, and in day-to-day practice in geriatrics. With further progress in medical science, we hope to see fewer and fewer hopeless cases. However, let us not allow ourselves to be seduced by this achievement. We will continue to see
INTERRUPTION OF CIRCULATION AS A THERAPEUTIC MEASURE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comment: conservatism vs radicalism in treatment
Authors: P. Rubin
Journal: JAMA (1968)

The survival results in bladder cancer become poorer as the treatment becomes more radical. In Jewett's report, for stage A lesions, transurethral resection provides a 70% success rate, whereas total cystectomy provides only 50%. For stage Bl, there is little difference in survival with the more aggressive procedures (50% ± 5%). Examination of the radiation results offered by Friedman again illustrates that the more conservative method of treatment (radium as a central source) yields a three-year survival rate, which is distinctly superior to the rate with 2 mev x-ray irradiation therapy, 93% vs 62%, respectively. This observation was also found in the detailed analysis of the experience at the Royal Marsden Hospital in London.<sup>16</sup> Although the figures clearly argue for conservatism in therapy, the truth lies in the unreported facts. The selection of one criterion, depth of penetration, is inadequate to make the patients in any series comparable. In
Screening for alcohol abuse
Authors: R. B. Lacoursiere
Journal: JAMA (1980)

<h3>In Reply.—</h3> The purpose of our article was to alert physicians to the frequency with which disorders of the hypothalamic-pituitary-gonadal axis occur in patients whose initial complaint is impotence. Parenthetically, the word impotence, defined in Merriam-Webster's as "a physical or psychological abnormal state of a male characterized by inability to copulate," is perfectly clear, understood by all, and preferable to the currently trendy bland euphemism "erection problems." Dr Kavich-Sharon's contention that we need more information to fully understand the biochemistry of sexual function and dysfunction is, of course, correct. We neither recommend nor condone the use of a therapeutic trial of testosterone therapy in impotent patients who have normal serum testosterone values. The treatment is reserved for those who, for one reason or another, are unable to produce adequate amounts of testosterone spontaneously. The reference to our patients as last resort is unwarranted. We did have some concern that the
Abstract 354: Combination of Triiodothyronine and Dexamethasone with Flexible Matrigel Substrate Improves Structural and Electrophysiological Maturation of Human iPSC-derived Cardiomyocytes
Authors: Lili Wang, Maria de las nieves Gomez-hurtado, Daniel Blackwell, Kyungsoo Kim, Shan Parikh, Bjorn C Knollmann
Journal: Circulation Research (2017)

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have promise for disease modeling and cell therapy, but electrophysiological immaturity (ie. large pacemaker currents, small I K1 ) and structural immaturity (ie. lack of t-tubules) remain major limitations. Here, we test whether the combination of triiodothyronine (T 3 ) and dexamethasone (Dex) with a soft Matrigel substrate improves hiPSC-CMs maturity. T 3 &amp; Dex or vehicle were added to cardiac induction media for 14 days. Day 30 hiPSC-CMs were plated either on hard or soft Matrigel-coated substrate for 5 days and studied using confocal imaging and voltage clamp. T 3 &amp; Dex treatment significantly increased the width and volume of hiPSC-CMs cultured on soft but not on hard substrate ( Fig.1 ). T 3 &amp; Dex treated hiPSC-CMs exhibited organized subcellular Ca release ( Fig.2 ) and evidence of t-tubule development, possibly as a result of increased Bin-1 and Caveolin-3 membrane trafficking. The combination of T 3 &amp; Dex and soft substrate increased Ca spark frequency and the amount of Ca released per spark ( Fig.3 ). T 3 &amp; Dex treatment significantly accelerated Ca transient decay under field stimulation and increased sarcoplasmic reticulum Ca-ATPase activity. Compared to vehicle, T 3 &amp; Dex treatment significantly improved electrophysiological maturity: Pacemaker current (I f ) density was 3-fold reduced (-2.7±0.35 vs. -6.2±1.3 pA/pF) and inward rectifier current (I K1 ) density was 4-fold increased (-19.3±2.2 vs. -4.4±0.5 pA/pF). Combining T 3 &amp; Dex and soft Matrigel substrate enhances structural and functional maturation of hiPSC-CMs, which will increase the utility of hiPSC-CM for disease modeling and cell therapy.